Amneal Pharmaceuticals, Inc. AMRX Specialty — Milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:MilestonesExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — milestones?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — milestones of $0 in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — milestones changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — milestones decreased by 100.0% year-over-year, from $3M to $0.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — milestones?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — milestones has grown at a 10.1% compound annual growth rate (CAGR), from $4.5M to $6M.
- What does specialty — milestones mean?
- Reflects payments made upon the achievement of specific regulatory, clinical, or commercial milestones related to specialty product development. These costs are typically associated with licensing agreements or collaborative research partnerships.